Effect of dexamethasone, bortezomib, and thalidomide dosing on clinical outcomes in relationship to glucocorticoid receptor gene (NR3C1) expression tertile (univariate analyses)
| Variable . | Lowest NR3C1 tertile (N = 91) . | Middle NR3C1 tertile (N = 92) . | Top NR3C1 tertile (N = 91) . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| OS | ||||||
| Dexamethasone during induction (all stages of induction combined, dg)* | 0.57 (0.40, 0.79) | < .001 | 0.71 (0.48, 1.04) | .081 | 1.38 (0.73, 2.60) | .322 |
| Dexamethasone during transplantation (dg)* | 0.93 (0.77, 1.13) | .481 | 0.89 (0.74, 1.06) | .193 | 0.93 (0.74, 1.16) | .509 |
| Dexamethasone during consolidation (dg)* | 0.85 (0.72, 1.02) | .082 | 0.79 (0.67, 0.92) | .002 | 0.91 (0.75, 1.11) | .354 |
| Dexamethasone during maintenance (dg)* | 0.92 (0.85, 1.00) | .045 | 0.94 (0.89, 1.00) | .057 | 0.94 (0.87, 1.02) | .144 |
| Bortezomib during induction (mg)* | 0.95 (0.83, 1.10) | .499 | 0.78 (0.69, 0.88) | < .001 | 0.92 (0.73, 1.15) | .441 |
| Bortezomib during consolidation (mg)* | 0.94 (0.86, 1.01) | .108 | 0.93 (0.87, 1.00) | .042 | 0.97 (0.89, 1.06) | .500 |
| Bortezomib during maintenance (mg)* | 0.99 (0.97, 1.01) | .160 | 1.00 (0.99, 1.01) | .766 | 0.98 (0.96, 1.01) | .168 |
| Thalidomide during induction (all stages of induction combined, dg)* | 0.49 (0.29, 0.83) | .008 | 0.83 (0.44, 1.57) | .572 | 1.01 (0.42, 2.40) | .988 |
| Thalidomide during transplantation (g)* | 0.86 (0.74, 1.01) | .064 | 0.94 (0.83, 1.07) | .334 | 0.91 (0.77, 1.09) | .307 |
| Thalidomide during consolidation (g)* | 0.86 (0.75, 0.98) | .029 | 0.93 (0.85, 1.02) | .122 | 0.97 (0.86, 1.10) | .658 |
| Thalidomide during maintenance (g)* | 0.97 (0.94, 1.01) | .148 | 1.00 (0.97, 1.02) | .753 | 0.98 (0.94, 1.02) | .338 |
| EFS | ||||||
| Dexamethasone during induction (all stages of induction combined, dg)* | 0.62 (0.46, 0.85) | .003 | 0.72 (0.50, 1.05) | .088 | 1.38 (0.75, 2.53) | .302 |
| Dexamethasone during transplantation (dg)* | 0.91 (0.77, 1.08) | .284 | 0.90 (0.76, 1.06) | .201 | 0.85 (0.69, 1.06) | .152 |
| Dexamethasone during consolidation (dg)* | 0.95 (0.82, 1.09) | .458 | 0.83 (0.72, 0.96) | .012 | 0.87 (0.71, 1.06) | .161 |
| Dexamethasone during maintenance (dg)* | 0.97 (0.91, 1.02) | .247 | 0.97 (0.91, 1.02) | .233 | 0.96 (0.89, 1.04) | .336 |
| Bortezomib during induction (mg)* | 0.96 (0.85, 1.09) | .572 | 0.80 (0.71, 0.90) | < .001 | 0.92 (0.74, 1.14) | .452 |
| Bortezomib during consolidation (mg)* | 0.98 (0.91, 1.05) | .578 | 0.94 (0.88, 1.01) | .089 | 0.95 (0.87, 1.04) | .297 |
| Bortezomib during maintenance (mg)* | 1.00 (0.99, 1.01) | .429 | 1.00 (0.99, 1.01) | .898 | 0.98 (0.95, 1.01) | .132 |
| Thalidomide during induction (all stages of induction combined, dg)* | 0.51 (0.32, 0.80) | .004 | 0.83 (0.46, 1.50) | .541 | 1.46 (0.65, 3.26) | .361 |
| Thalidomide during transplantation (g)* | 0.85 (0.74, 0.98) | .022 | 0.95 (0.85, 1.07) | .422 | 0.90 (0.76, 1.05) | .186 |
| Thalidomide during consolidation (g)* | 0.96 (0.88, 1.05) | .372 | 0.94 (0.86, 1.03) | .167 | 0.98 (0.87, 1.10) | .703 |
| Thalidomide during maintenance (g)* | 0.99 (0.96, 1.01) | .354 | 1.01 (0.98, 1.03) | .592 | 1.00 (0.96, 1.03) | .801 |
| Variable . | Lowest NR3C1 tertile (N = 91) . | Middle NR3C1 tertile (N = 92) . | Top NR3C1 tertile (N = 91) . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| OS | ||||||
| Dexamethasone during induction (all stages of induction combined, dg)* | 0.57 (0.40, 0.79) | < .001 | 0.71 (0.48, 1.04) | .081 | 1.38 (0.73, 2.60) | .322 |
| Dexamethasone during transplantation (dg)* | 0.93 (0.77, 1.13) | .481 | 0.89 (0.74, 1.06) | .193 | 0.93 (0.74, 1.16) | .509 |
| Dexamethasone during consolidation (dg)* | 0.85 (0.72, 1.02) | .082 | 0.79 (0.67, 0.92) | .002 | 0.91 (0.75, 1.11) | .354 |
| Dexamethasone during maintenance (dg)* | 0.92 (0.85, 1.00) | .045 | 0.94 (0.89, 1.00) | .057 | 0.94 (0.87, 1.02) | .144 |
| Bortezomib during induction (mg)* | 0.95 (0.83, 1.10) | .499 | 0.78 (0.69, 0.88) | < .001 | 0.92 (0.73, 1.15) | .441 |
| Bortezomib during consolidation (mg)* | 0.94 (0.86, 1.01) | .108 | 0.93 (0.87, 1.00) | .042 | 0.97 (0.89, 1.06) | .500 |
| Bortezomib during maintenance (mg)* | 0.99 (0.97, 1.01) | .160 | 1.00 (0.99, 1.01) | .766 | 0.98 (0.96, 1.01) | .168 |
| Thalidomide during induction (all stages of induction combined, dg)* | 0.49 (0.29, 0.83) | .008 | 0.83 (0.44, 1.57) | .572 | 1.01 (0.42, 2.40) | .988 |
| Thalidomide during transplantation (g)* | 0.86 (0.74, 1.01) | .064 | 0.94 (0.83, 1.07) | .334 | 0.91 (0.77, 1.09) | .307 |
| Thalidomide during consolidation (g)* | 0.86 (0.75, 0.98) | .029 | 0.93 (0.85, 1.02) | .122 | 0.97 (0.86, 1.10) | .658 |
| Thalidomide during maintenance (g)* | 0.97 (0.94, 1.01) | .148 | 1.00 (0.97, 1.02) | .753 | 0.98 (0.94, 1.02) | .338 |
| EFS | ||||||
| Dexamethasone during induction (all stages of induction combined, dg)* | 0.62 (0.46, 0.85) | .003 | 0.72 (0.50, 1.05) | .088 | 1.38 (0.75, 2.53) | .302 |
| Dexamethasone during transplantation (dg)* | 0.91 (0.77, 1.08) | .284 | 0.90 (0.76, 1.06) | .201 | 0.85 (0.69, 1.06) | .152 |
| Dexamethasone during consolidation (dg)* | 0.95 (0.82, 1.09) | .458 | 0.83 (0.72, 0.96) | .012 | 0.87 (0.71, 1.06) | .161 |
| Dexamethasone during maintenance (dg)* | 0.97 (0.91, 1.02) | .247 | 0.97 (0.91, 1.02) | .233 | 0.96 (0.89, 1.04) | .336 |
| Bortezomib during induction (mg)* | 0.96 (0.85, 1.09) | .572 | 0.80 (0.71, 0.90) | < .001 | 0.92 (0.74, 1.14) | .452 |
| Bortezomib during consolidation (mg)* | 0.98 (0.91, 1.05) | .578 | 0.94 (0.88, 1.01) | .089 | 0.95 (0.87, 1.04) | .297 |
| Bortezomib during maintenance (mg)* | 1.00 (0.99, 1.01) | .429 | 1.00 (0.99, 1.01) | .898 | 0.98 (0.95, 1.01) | .132 |
| Thalidomide during induction (all stages of induction combined, dg)* | 0.51 (0.32, 0.80) | .004 | 0.83 (0.46, 1.50) | .541 | 1.46 (0.65, 3.26) | .361 |
| Thalidomide during transplantation (g)* | 0.85 (0.74, 0.98) | .022 | 0.95 (0.85, 1.07) | .422 | 0.90 (0.76, 1.05) | .186 |
| Thalidomide during consolidation (g)* | 0.96 (0.88, 1.05) | .372 | 0.94 (0.86, 1.03) | .167 | 0.98 (0.87, 1.10) | .703 |
| Thalidomide during maintenance (g)* | 0.99 (0.96, 1.01) | .354 | 1.01 (0.98, 1.03) | .592 | 1.00 (0.96, 1.03) | .801 |
Univariate analyses were performed of cumulative doses per protocol step (induction, peritransplantation, consolidation, and maintenance), within each GEP NR3C1 tertile.
Variable was treated as a time-dependent variable.